Evidence map›Paper›PMID 36182938›Full record

ArticleScientific data2022

COLONOMICS - integrative omics data of one hundred paired normal-tumoral samples from colon cancer patients.

Anna Díez-Villanueva, Rebeca Sanz-Pamplona, Xavier Solé, David Cordero, Marta Crous-Bou, Elisabet Guinó, Adriana Lopez-Doriga, Antoni Berenguer, Susanna Aussó, Laia Paré-Brunet and 12 more

Erratum issuedOpen access · goldAbstract readDataset
In one paragraph

Article in Scientific data, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 3 countries.

Anna Díez-VillanuevaOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Rebeca Sanz-PamplonaOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2187-3527
Xavier SoléMolecular Biology CORE, Center for Biomedical Diagnostics, Hospital Clínic de Barcelona, 08036, Barcelona, Spain.
David CorderoOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Marta Crous-BouUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
Elisabet GuinóOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Adriana Lopez-DorigaOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Antoni BerenguerRheumatology Department - Parc Taulí Research and Innovation Institute (I3PT), Barcelona, Spain.
Susanna AussóTIC Salut Social Foundation. Ministry of Health of Generalitat de Catalunya, Barcelona, Spain.
Laia Paré-BrunetReveal Genomics. S.L., Barcelona, Spain.
Mireia Obón-SantacanaOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Ferran Moratalla-NavarroOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Ramon SalazarColorectal Cancer Group, ONCOBELL, Bellvitge Biomedical Research Institute (IDIBELL). Hospitalet de Llobregat, Barcelona, Spain.
Xavier SanjuanDepartment of Clinical Sciences, Faculty of Medicine and health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain.
Cristina SantosColorectal Cancer Group, ONCOBELL, Bellvitge Biomedical Research Institute (IDIBELL). Hospitalet de Llobregat, Barcelona, Spain.
Sebastiano BiondoDepartment of Clinical Sciences, Faculty of Medicine and health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain.
Virginia Diez-ObreroOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Ainhoa Garcia-SerranoOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Maria Henar AlonsoOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Robert Carreras-TorresOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.
Adria ClosaThe John Curtin School of Medical Research, Australian National University, Canberra, Australia.
Víctor MorenoOncology Data Analytics Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain. v.moreno@iconcologia.net.ORCID http://orcid.org/0000-0002-2818-5487
Institut d'Investigació Biomédica de Bellvitge · ESBellvitge University Hospital · ESAustralian National University · AUGeneralitat de Catalunya · ESHarvard University · USHospital Clínic de Barcelona · ESInstitute of Research and Innovation Parc Tauli · ESOryzon Genomics (Spain) · ES

Funding

Transdisciplinary Studies of Genetic Variation in Colorectal CancerU19CA148107 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GRUBER, STEPHEN B · 2010 to 2014
$11.1M
Using Functional Genomics to Inform Gene Environment Interactions for Colorectal CancerR01CA201407 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CASEY, GRAHAM, GAUDERMAN, WILLIAM JAMES · 2016 to 2020
$9.6M
NCI NIH HHS R01 CA201407NCI NIH HHS U19 CA148107
6 · The paper itself

Abstract

Colonomics is a multi-omics dataset that includes 250 samples: 50 samples from healthy colon mucosa donors and 100 paired samples from colon cancer patients (tumor/adjacent). From these samples, Colonomics project includes data from genotyping, DNA methylation, gene expression, whole exome sequencing and micro-RNAs (miRNAs) expression. It also includes data from copy number variation (CNV) from tumoral samples. In addition, clinical data from all these samples is available. The aims of the project were to explore and integrate these datasets to describe colon cancer at molecular level and to compare normal and tumoral tissues. Also, to improve screening by finding biomarkers for the diagnosis and prognosis of colon cancer. This project has its own website including four browsers allowing users to explore Colonomics datasets. Since generated data could be reuse for the scientific community for exploratory or validation purposes, here we describe omics datasets included in the Colonomics project as well as results from multi-omics layers integration.

Indexed as

Colonic NeoplasmsMicroRNAsBiomarkersDNA Copy Number VariationsHumansPrognosisBiomarkersMicroRNAs

Identifiers

PMID36182938
PMCPMC9526730
OpenAlexW4298342338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.